Advate

Prevention & control of haemorrhagic episodes & peri-op management in haemophilia A.

IV Individualised dosage. Haemorrhage: Early haemarthosis, muscle or oral bleeding 20-40 IU/dL every 12-24 hr for at least 1 day until bleeding episode, as indicated by pain is resolved or healing is achieved; more extensive haemarthosis, muscle bleeding or haematoma 30-60 IU/dL every 12-24 hr for 3-4 days or more until pain & acute disability are resolved; life-threatening haemorrhage 60-100 IU/dL every 8-24 hr until threat is resolved. Surgery: Minor (including tooth extraction) 30-60 IU/dL every 24 hr for at least 1 day until healing is achieved; major (pre- & post-op) 80-100 IU/dL every 8-24 hr until adequate wound healing, then continue therapy for at least another 7 days to maintain a factor VIII activity of 30-60% or IU/dL.

Hypersensitivity to octocog alfa (recombinant human coagulation factor VIII), mouse or hamster proteins.

Haemostatics

B02BD02 - coagulation factor VIII ; Belongs to the class of blood coagulation factors. Used in the treatment of hemorrhage.

POM